Navigation

News

Your contact person

Manager PR & Communications Jan Phillip Denkers

Filter reset
Tiprelestat will be administered to patients hospitalized due to COVID-19 with the goal of reducing the duration of severe COVID-19.
Tiprelestat will be administered to patients hospitalized due to COVID-19 with the goal of reducing the duration of severe COVID-19. (Photo Credit: Alissa Eckert, MSMI; Dan Higgins, MAMS)

tiakis: Treatment of COVID-19

tiakis Biotech AG announced today that a first patient has been dosed in the COMCOVID trial, a Phase Ib/II trial evaluating the Company’s key investigational ...

Read more …
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life threatening surgeries and life-threatening diseases such as PAH and COVID-19.
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life threatening surgeries and life-threatening diseases such as PAH and COVID-19. (Image: ©stock.adobe.com/Gorodenkoff)

tiakis Biotech AG and Northway Biotech collaborate

tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful ...

Read more …